Synagis Injection, Solution
Product Images NDC 66658-231

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Synagis (NDC 66658-231). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Swedish Orphan Biovitrum Ab (publ), these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Syn01 0003 01

Syn01 0003 01
This is a description of a prescription drug called SYNAGIS® used for intramuscular injection only. It contains Palivizumab, a humanized monoclonal antibody used to treat Respiratory Syncytial Virus (RSV) infections. Each vial contains 50mg of Palivizumab per 0.5ml of solution, along with histidine, glycine, and chloride. The medicine does not contain preservatives, and the unused portion should be discarded. The recommended dose is 15mg/kg intramuscularly, and a doctor's prescription is required to use the drug.*
FDA Label Image

Syn01 0003 02

Syn01 0003 02
This is a description for a medication called SYNAGIS (PALIVIZUMAB). It is for intramuscular injection only and each dose is 15 mg/kg. The medication comes in a container with the NDC code 66658-230-01. The text also includes a warning to discard any unused portion and the statement that it does not contain preservatives.*
FDA Label Image

Syn01 0003 03

Syn01 0003 03
This is a description of a medication called SYNAGIS or Palivizumab. It is manufactured by a company called Swedish Orphan Biovirum AB in Stockholm, Sweden. The medication is an intramuscular injection used to treat respiratory syncytial virus (RSV) and contains 100mg Palivizumab, which is a recombinant humanized monoclonal antibody to RSV. It comes in a vial and each vial contains 1 mL of solution, which includes 39mg histidine, 0.1mg glycine, and 0.5mg chiorde, with no preservatives. The medication should be used immediately after drawing the dose into the syringe, and any unused portion should be discarded. The recommended dose is 15mg/kg, and the package insert should be consulted for further information.*
FDA Label Image

Syn01 0003 04

Syn01 0003 04
This is a description of a prescription medication called SYNAGIS (Palivizumab) by Swedish Orphan. It is used for intramuscular injection to prevent respiratory syncytial virus (RSV) infections in infants and young children. The medication is supplied in a 100 mg/mL concentration and does not contain any preservatives. The recommended dose is 15 mg/kg. The National Drug Code (NDC) for this medication is 66658-231-01. This medication is available only by prescription.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.